Skip to Main Content

Paper Details

ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.
Clin Cancer Res
35
2018
ATP, BRAF, BRAF/RAS-mutant cancer cell lines, EGFR, ERBB receptor, ERBB2, ERK, ERK mutations, ERK1/2, ERK2, MAPK, MEK, PI3K, RAF, RAF- and, RAF- and/or RAS-mutated tumors, RAS, cancer, mTOR, mutant ERK, patients, resistant lines, tumor
Author NameAffiliation
Steffen DurinckGenentech Inc.
Steffen DurinckGenentech Inc.
  • 1 - 2

Datasets

Release 1.2